Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Crystal Structures Define Mode of Action of Bacteriophage Endolysins

By BiotechDaily International staff writers
Posted on 13 Aug 2014
Print article
Image: Electron microscopy image of the bacteriophages investigated (Photo courtesy of the European Molecular Biology Laboratory).
Image: Electron microscopy image of the bacteriophages investigated (Photo courtesy of the European Molecular Biology Laboratory).
Image: The analyzed endolysins are activated by switching from a tensed, stretched state (left) to a relaxed state (right) (Photo courtesy of the European Molecular Biology Laboratory).
Image: The analyzed endolysins are activated by switching from a tensed, stretched state (left) to a relaxed state (right) (Photo courtesy of the European Molecular Biology Laboratory).
New antibacterial agents based on bacteriophages or their endolysin enzymes have been proposed to solve the problem of the bacterium Clostridium difficile, which is becoming a serious health hazard in hospitals and healthcare institutes, due to its resistance to antibiotics.

Investigators at the European Molecular Biology Laboratory (Hamburg, Germany) based their research primarily on the bacteriophage CD27, which is capable of lysing C. difficile. In addition, they worked with a recombinant form of the CD27L endolysin, which lyses C. difficile in vitro.

To better understand how the lysis process works, the investigators determined the three-dimensional structures of the CD27L endolysin and the CTP1L endolysin from the closely related bacteriophage CPT1 that targets C. tyrobutyricum. For this task they employed X-ray crystallography and small angle X-ray scattering (SAXS), which was done at the Deutsches Elektronen-Synchrotron (DESY).

Results published in the July 24, 2014, online edition of the journal PLOS Pathogens revealed that the two endolysins shared a common activation mechanism, despite having been taken from different species of Clostridium. The activation mechanism depended on a structure where an extended dimer existed in the inactive state but switched to a side-by-side "relaxed" morphology in the active state, which triggered the cleavage of the C-terminal domain. This change of morphology led to the release of the catalytic portion of the endolysin, enabling the efficient digestion of the bacterial cell wall.

“These enzymes appear to switch from a tense, elongated shape, where a pair of endolysins is joined together, to a relaxed state where the two endolysins lie side-by-side,” said first author Dr. Matthew Dunne, a researcher at the European Molecular Biology Laboratory. “The switch from one conformation to the other releases the active enzyme, which then begins to degrade the cell wall.”

Related Links:

European Molecular Biology Laboratory



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.